➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Johnson and Johnson
Moodys
Mallinckrodt
Baxter

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

Ge Healthcare Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Ge Healthcare
International Patents:116
US Patents:7
Tradenames:57
Ingredients:38
NDAs:49
Drug Master File Entries: 5

Drugs and US Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare AMIPAQUE metrizamide INJECTABLE;INJECTION 017982-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes 8,236,282   Start Trial Y Y   Start Trial
Ge Healthcare CINTICHEM TECHNETIUM 99M HEDSPA technetium tc-99m etidronate kit INJECTABLE;INJECTION 017653-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Ge Healthcare TECHNETIUM TC 99M GENERATOR technetium tc-99m sodium pertechnetate generator SOLUTION;INTRAVENOUS, ORAL 017693-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Ge Healthcare TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT technetium tc-99m etidronate kit INJECTABLE;INJECTION 017562-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Ge Healthcare TELEPAQUE iopanoic acid TABLET;ORAL 008032-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Ge Healthcare OMNIPAQUE 210 iohexol INJECTABLE;INJECTION 018956-006 Jun 30, 1989 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OMNIPAQUE 300 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-003 Dec 26, 1985 4,396,597   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-001 Sep 5, 2007 5,560,903   Start Trial
Ge Healthcare OMNIPAQUE 140 iohexol INJECTABLE;INJECTION 018956-005 Nov 30, 1988 4,250,113   Start Trial
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020351-002 Mar 22, 1996 4,396,597   Start Trial
Ge Healthcare ISOPAQUE 280 calcium; meglumine; metrizoic acid INJECTABLE;INJECTION 017506-001 Approved Prior to Jan 1, 1982 3,476,802   Start Trial
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-002 Dec 26, 1985 4,396,597   Start Trial
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-002 Dec 26, 1985 4,021,481   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Ge Healthcare Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0290047 SPC/GB97/078 United Kingdom   Start Trial PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
2182988 6/2015 Austria   Start Trial PRODUCT NAME: (18F) - FLUTEMETAMOL; REGISTRATION NO/DATE: EU/1/14/941 (MITTEILUNG) 20140826
0268956 1999C0030 Belgium   Start Trial PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
2673237 1990016-6 Sweden   Start Trial PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; REG. NO/DATE: EU/1/17/1173 20180326
1758590 LUC00029 Luxembourg   Start Trial PRODUCT NAME: SEL DE SODIUM D'ACIDE DEOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: IS/1/16/071/01 20170401
2957286 132019000000021 Italy   Start Trial PRODUCT NAME: PATIROMER SORBITEX CALCIUM E QUALSIASI SUO SALE O DERIVATO(VELTASSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1179, 20170721
1611115 92634 Luxembourg   Start Trial PRODUCT NAME: FLUTEMETAMOL (18F) ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZAMYL). FIRST REGISTRATION: 20140826
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Moodys
Dow
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.